Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 5/20 | 0.61 |
| ▸ | RAF1 | P04049 | 1/20 | 0.57 |
| ▸ | YES1 | P07947 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 11/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15939192 | 0.90 | BRAF (0.60) | BRAFRAF1YES1KDM4EMAPK14 | |
| SCHEMBL4164155 | 0.88 | BRAF (0.65) | BRAFRAF1YES1KDM4EMAPK14 | |
| SCHEMBL20133847 | 0.84 | BRAF (0.69) | BRAFRAF1YES1KDM4EMAPK14 | |
| SCHEMBL4166506 | 0.83 | BRAF (0.64) | BRAFRAF1YES1KDM4EMAPK14 | |
| Hydrochloric Acid SCHEMBL15939103 | 0.82 | BRAF (0.63) | BRAFRAF1YES1KDM4EMAPK14 | |
| SCHEMBL29606390 | 0.82 | KDM4E (0.57) | KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL4181343 | 0.82 | KDM4E (0.57) | KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL27682671 | 0.81 | MAPK14 (0.69) | BRAFRAF1YES1KDM4EMAPK14 | |
| SCHEMBL27682670 | 0.80 | BRAF (0.69) | BRAFRAF1YES1KDM4EMAPK14 | |
| SCHEMBL4242038 | 0.80 | BRAF (0.64) | BRAFRAF1YES1KDM4EMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170849-A1 | QUINAZOLINONE DERIVATIVES HAVING B-RAF INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2009-07-02 | — | — | US | disclosed |
| CN-101415688-A | Quinazolone derivative with B-RAF inhibition activity | ASTRAZENECA AB (SE) | 2009-04-22 | — | — | CN | disclosed |
| EP-2007737-A2 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007113558-A2 | QUINAZOLINONE DERIVATIVES HAVING B-RAF INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170849-A1 | QUINAZOLINONE DERIVATIVES HAVING B-RAF INHIBITORY ACTIVITY | BRAF, ARAF, RAF1 | BRAF 1/4885RAF1 3/4885YES1 941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.